瑞麗醫美(02135.HK)公佈中期業績 收益增長56% 醫療美容活躍客户增加39.4%
格隆匯8月20日丨瑞麗醫美(02135.HK)發佈公吿，截至2021年6月30日止六個月，於期內公司的醫療美容服務從疫情的影響中逐步恢復，公司收益9149萬元人民幣，同比增長56%；毛利3710萬元，同比增長53%。
於期內，公司的醫療美容服務總收入及醫療美容管理諮詢服務分別約為人民幣8920萬元及人民幣230萬元，較截至2020年6月30日止六個月的醫療美容服務總收入及醫療美容管理諮詢服務分別約人民幣5750萬元及人民幣130萬元相比，分別增長了約55.2%及83.3%。
於期內，公司醫療美容活躍客户數量為43,325名，較2020年上半年活躍客户31,080名增加了39.4%，新客户數量及回頭客數量分別為16,130名及27,195名，較截至2020年6月30日止六個月的新客户13,928名及回頭客數量17,152名分別增長了15.8%和58.6%。於期內，公司醫療美容服務的每位客户的平均消費約為人民幣2,059元，較截至2020年6月30日止六個月的每位客户平均消費約人民幣1,849元增長了約11.4%。活躍客户數量的增加，及每位活躍客户的平均消費的增加，都證明了公司成功應對了消費者行為的轉變。
考慮到客户數量的迅速增長及消費情緒回升，公司通過全面實施改擴建計劃以改善公司醫療美容機構的環境。公司一直在改造及擴建蕪湖瑞麗，擴建的總建築面積約為1,500平方米。蕪湖瑞麗的客户接待區域將會增大，並增設若干房間，包括3間手術室、12間治療室等。蕪湖瑞麗預計於本年第四季度完成改擴建。
升級改造完成後，公司相信能夠提高我們的服務能力並改善客户的用户體驗。預計完成現有醫療機構的改擴建後，公司的醫療美容機構的總建築面積將從截至2020年6月30日止六個月的約7,972平方米增加至約12,672平方米，增長59.0%。
此外，2021年上半年，公司是中國整形美容協會中小醫美機構2021幫扶計劃的主要承辦單位。該計劃旨在支持中小醫美機構的發展，該計劃第一階段覆蓋了全國19個省，並覆蓋了800多家醫美機構。通過參與該計劃，我們與多家中小機構建立合作關係並於業內建立良好的品牌聲譽。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
